|
CA2448382C
(en)
|
2001-05-25 |
2013-02-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Use of hepcidin as a regulator of iron homeostasis
|
|
KR102236829B1
(ko)
*
|
2013-03-15 |
2021-04-07 |
프로타고니스트 테라퓨틱스, 인코포레이티드 |
헵시딘 유사체 및 이의 용도
|
|
US11504346B2
(en)
|
2013-11-03 |
2022-11-22 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Redox-activated pro-chelators
|
|
US12383518B2
(en)
|
2013-11-03 |
2025-08-12 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Disulfide-masked pro-chelator compositions and methods of use
|
|
AU2015258863B2
(en)
|
2014-05-16 |
2019-10-24 |
Protagonist Therapeutics, Inc. |
Alpha4beta7 integrin thioether peptide antagonists
|
|
AU2015289642B2
(en)
|
2014-07-17 |
2021-02-25 |
Protagonist Therapeutics, Inc. |
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
|
|
WO2016054411A1
(en)
|
2014-10-01 |
2016-04-07 |
Protagonist Therapeutics, Inc. |
NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
|
|
EP3201217A4
(en)
|
2014-10-01 |
2018-07-18 |
Protagonist Therapeutics Inc. |
Novel cyclic monomer and dimer peptides having integrin antagonist activity
|
|
US10787490B2
(en)
|
2015-07-15 |
2020-09-29 |
Protaganist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
WO2017117411A1
(en)
*
|
2015-12-30 |
2017-07-06 |
Protagonist Therapeutics, Inc. |
Analogues of hepcidin mimetics with improved in vivo half lives
|
|
KR20180109917A
(ko)
*
|
2016-01-08 |
2018-10-08 |
라 졸라 파마슈티칼 컴파니 |
헵시딘의 투여 방법
|
|
EP3432906A4
(en)
|
2016-03-23 |
2020-04-01 |
Protagonist Therapeutics, Inc. |
METHOD FOR SYNTHETIZING ALPHA4BETA7 PEPTIDE ANTAGONISTS
|
|
AU2017324446A1
(en)
*
|
2016-09-06 |
2019-03-28 |
La Jolla Pharmceutical Company |
Methods of treating iron overload
|
|
AU2017378976A1
(en)
*
|
2016-12-19 |
2019-07-04 |
La Jolla Pharmaceutical Company |
Methods of administering hepcidin
|
|
WO2018128828A1
(en)
|
2016-12-23 |
2018-07-12 |
Bayer Healthcare Llc |
Novel hepcidin mimetics and uses thereof
|
|
US20200170971A1
(en)
*
|
2017-07-18 |
2020-06-04 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Disulfide-masked pro-chelator compositions and methods of use
|
|
US10278957B2
(en)
|
2017-09-11 |
2019-05-07 |
Protagonist Therapeutics, Inc. |
Opioid agonist peptides and uses thereof
|
|
EP3749345A4
(en)
|
2018-02-08 |
2022-04-06 |
Protagonist Therapeutics, Inc. |
CONJUGATED HEPCIDIN MIMETICS
|
|
TW202019948A
(zh)
|
2018-07-12 |
2020-06-01 |
美商領導醫療有限公司 |
介白素-23受體之肽抑制劑及其治療發炎疾病之用途
|
|
US11286243B2
(en)
|
2018-12-13 |
2022-03-29 |
Global Blood Therapeutics, Inc. |
Ferroportin inhibitors and methods of use
|
|
CN114585637B
(zh)
|
2019-05-07 |
2025-04-15 |
拜耳公司 |
Masp抑制化合物及其用途
|
|
MX2022000397A
(es)
|
2019-07-10 |
2022-04-25 |
Protagonist Therapeutics Inc |
Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
|
|
EP4025592B1
(en)
*
|
2019-09-03 |
2025-10-29 |
Protagonist Therapeutics, Inc. |
Conjugated hepcidin mimetics for use in treating of polycythemia vera
|
|
WO2021062171A1
(en)
*
|
2019-09-27 |
2021-04-01 |
Disc Medicine, Inc. |
Methods for treating anemia of chronic disease
|
|
JP2022549506A
(ja)
*
|
2019-09-27 |
2022-11-25 |
ディスク・メディシン・インコーポレイテッド |
骨髄線維症および関連状態を処置するための方法
|
|
KR20220141808A
(ko)
|
2020-01-15 |
2022-10-20 |
얀센 바이오테크 인코포레이티드 |
인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
|
|
CN118063554A
(zh)
|
2020-01-15 |
2024-05-24 |
詹森生物科技公司 |
介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
|
|
CA3181577A1
(en)
|
2020-04-28 |
2021-11-04 |
Global Blood Therapeutics, Inc. |
Thieno pyrimidines as ferroportin inhibitors
|
|
PE20230845A1
(es)
|
2020-04-28 |
2023-05-23 |
Global Blood Therapeutics Inc |
Pirimidinas cicloalquiladas como inhibidores de la ferroportina
|
|
US20230226074A1
(en)
|
2020-04-28 |
2023-07-20 |
Global Blood Therapeutics, Inc. |
Methods of use for pyrimidines as ferroportin inhibitors
|
|
KR20230012539A
(ko)
|
2020-05-13 |
2023-01-26 |
디스크 메디슨, 인크. |
골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
|
|
CN111560051B
(zh)
*
|
2020-05-26 |
2022-11-25 |
大连工业大学 |
一种具有促铁吸收活性的虾源九肽及其应用
|
|
US20230324413A1
(en)
*
|
2020-07-02 |
2023-10-12 |
Tampere University Foundation Sr |
Renin-based analysis of hepcidin
|
|
KR20230053615A
(ko)
*
|
2020-07-28 |
2023-04-21 |
프로타고니스트 테라퓨틱스, 인코포레이티드 |
접합된 헵시딘 모방체
|
|
CN114252627A
(zh)
*
|
2020-09-24 |
2022-03-29 |
首都医科大学附属北京世纪坛医院 |
尿液铁调素及其多肽片段在过敏性疾病中的应用
|
|
KR20230110570A
(ko)
|
2020-11-20 |
2023-07-24 |
얀센 파마슈티카 엔.브이. |
인터류킨-23 수용체의 펩티드 억제제의 조성물
|
|
WO2022212696A1
(en)
*
|
2021-04-01 |
2022-10-06 |
Protagonist Therapeutics, Inc. |
Conjugated hepcidin mimetics
|
|
WO2022266060A1
(en)
|
2021-06-14 |
2022-12-22 |
Protagonist Therapeutics, Inc. |
Hepcidin mimetics for treatment of hereditary hemochromatosis
|
|
TW202330013A
(zh)
|
2021-07-14 |
2023-08-01 |
美商健生生物科技公司 |
介白素－２３受體之脂化肽抑制劑
|
|
CN115703826B
(zh)
*
|
2021-08-03 |
2025-05-06 |
浙江大学 |
铁调素改造体及其应用
|
|
EP4587034A1
(en)
*
|
2022-09-15 |
2025-07-23 |
Migal Galilee Research Institute Ltd |
Site-specific activation of regulatory t cells
|
|
WO2025224128A1
(en)
|
2024-04-24 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Methods of treatment of iron overload associated diseases by administration hepcidin locally in the gut
|